Showing results (251-260 of 1,297) with videos related to

Sort By:
Pageof 130
Diabetes Care|January 22, 2024
Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE TrialsSheldon W Tobe, Thomas A Mavrakanas, Harpreet S Bajaj, et al.
Diabetes, Obesity & Metabolism|August 17, 2021
Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysisKent Y Feng, JingWei Li, Juliana Ianus, et al.
Diabetes, Obesity & Metabolism|May 15, 2023
Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trialsVikas S Sridhar, Brendon L Neuen, Robert A Fletcher, et al.
Diabetes, Obesity & Metabolism|March 1, 2017
Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trialsBruce Neal, Vlado Perkovic, Kenneth W Mahaffey, et al.
European Journal of Heart Failure|January 23, 2025
Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: A participant-level pooled analysis of the CANVAS and CREDENCE trialsSafia Chatur, Muthiah Vaduganathan, Robert A Fletcher, et al.
The New England Journal of Medicine|June 25, 2020
Effects of Allopurinol on the Progression of Chronic Kidney DiseaseSunil V Badve, Elaine M Pascoe, Anushree Tiku, et al.
JACC. Heart Failure|November 3, 2019
Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 DiabetesJingWei Li, Mark Woodward, Vlado Perkovic, et al.
International Journal of Cardiology|September 26, 2020
An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trialsJie Yu, Zien Zhou, Kenneth W Mahaffey, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 4, 2022
Design and population of the VALOR-CKD study: a multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of veverimer in slowing progression of chronic kidney disease in patients with metabolic acidosisVandana S Mathur, David A Bushinsky, Lesley Inker, et al.
American Journal of Nephrology|November 3, 2021
The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline CharacteristicsMuh Geot Wong, Jicheng Lv, Michelle A Hladunewich, et al.
Pageof 130